Exploring These 3 Undervalued Small Caps With Insider Buying Across Regions
Over the last 7 days, the United States market has experienced a slight decline of 1.6%, yet it has shown a robust growth of 12% over the past year, with earnings projected to increase by 17% annually in the coming years. In this dynamic environment, identifying small-cap stocks that are perceived as undervalued and exhibit insider buying can be an effective strategy for investors seeking potential opportunities amidst fluctuating market conditions.
Top 10 Undervalued Small Caps With Insider Buying In The United States
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Financial Institutions | 9.9x | 3.3x | 21.41% | ★★★★★☆ |
| Enovis | NA | 0.5x | 45.68% | ★★★★★☆ |
| Bank of the James Financial Group | 10.8x | 2.4x | 26.89% | ★★★★☆☆ |
| Union Bankshares | 9.6x | 2.0x | 45.86% | ★★★★☆☆ |
| Shore Bancshares | 11.9x | 3.4x | 35.42% | ★★★★☆☆ |
| German American Bancorp | 13.2x | 4.9x | 26.06% | ★★★☆☆☆ |
| Franklin Financial Services | 11.7x | 3.2x | -42.84% | ★★★☆☆☆ |
| Citizens Community Bancorp | 16.4x | 3.6x | 8.60% | ★★★☆☆☆ |
| New Peoples Bankshares | 9.2x | 2.5x | 13.28% | ★★★☆☆☆ |
| Hanover Bancorp | 20.7x | 2.9x | 34.51% | ★★★☆☆☆ |
Here we highlight a subset of our preferred stocks from the screener.
Orchestra BioMed Holdings (OBIO)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Orchestra BioMed Holdings is a biomedical company focused on developing innovative therapeutic products in the surgical and medical equipment sector, with a market cap of $0.18 billion.
Operations: Orchestra BioMed Holdings generates revenue primarily from its Surgical & Medical Equipment segment, with recent figures showing $31.98 million in revenue. The company's cost structure includes significant operating expenses, notably in research and development and general and administrative areas. Despite a gross profit margin of 99.51%, the company has experienced negative net income margins over several periods, indicating ongoing financial challenges.
PE: -6.1x
Orchestra BioMed Holdings, a smaller company in the U.S., is experiencing significant insider confidence with recent share purchases. Despite its current unprofitability and reliance on external borrowing, revenue is projected to grow 46% annually. Recent earnings show a net loss of US$23.76 million for Q2 2026, but the company has been added to multiple Russell indices, suggesting potential market interest. Recent presentations at major conferences highlight their active engagement with investors and industry stakeholders.
- Click here and access our complete valuation analysis report to understand the dynamics of Orchestra BioMed Holdings.
Gain insights into Orchestra BioMed Holdings' past trends and performance with our Past report.
Financial Institutions (FISI)
Simply Wall St Value Rating: ★★★★★☆
Overview: Financial Institutions operates primarily in the banking sector with additional services in investment advisory, and it has a market capitalization of $0.34 billion.
Operations: The company's primary revenue stream is from banking, supplemented by investment advisory income. Operating expenses are significant, with general and administrative expenses consistently accounting for a large portion of costs. The net income margin has shown variability, reaching as high as 36.31% in recent quarters before experiencing fluctuations.
PE: 9.9x
Financial Institutions, Inc., a smaller player in the U.S. financial sector, showcases potential with its recent earnings growth. For Q2 2026, net income rose to US$21.18 million from US$17.53 million year-over-year, while net interest income increased to US$53.36 million from US$49.12 million. Despite no share repurchases in the latest quarter, insider confidence is evident through consistent dividend payouts of $0.32 per common share and preferred dividends on schedule for October 2, 2026.
- Click here to discover the nuances of Financial Institutions with our detailed analytical valuation report.
Evaluate Financial Institutions' historical performance by accessing our past performance report.
Caledonia Mining (CMCL)
Simply Wall St Value Rating: ★★★★☆☆
Overview: Caledonia Mining is a mining company primarily engaged in the operation and development of gold mines, with a market capitalization of approximately $0.11 billion.
Operations: The company generates revenue primarily from its Blanket segment, with additional contributions from operations in South Africa and the Bilboes Oxide Mine. The gross profit margin has shown variability, reaching 60.19% as of June 2026.
PE: 7.4x
Caledonia Mining, a smaller player in the U.S. market, has recently announced a maiden mineral resource estimate for its Motapa property in Zimbabwe, highlighting potential synergies with its adjacent Bilboes project. Despite relying on external borrowing for funding, the company demonstrates growth prospects with earnings forecast to rise by 35.84% annually. Recent insider confidence is evident through share purchases between July and August 2026. Meanwhile, Q2 earnings showed an increase in sales to US$75.91 million and net income of US$23.81 million compared to last year’s figures, reflecting operational improvements at their Blanket Mine with production guidance reaffirmed for 2026 at 72,000 to 76,500 ounces of gold output.
- Unlock comprehensive insights into our analysis of Caledonia Mining stock in this valuation report.
Assess Caledonia Mining's past performance with our detailed historical performance reports.
Key Takeaways
- Navigate through the entire inventory of 61 Undervalued US Small Caps With Insider Buying here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com